Reviewer's report

**Title:** Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

**Version:** 2  **Date:** 23 March 2015

**Reviewer:** Alena M. Pfeil

**Reviewer's report:**

Comments to the authors after revision

Major compulsory revisions:
1: In my opinion, the number of provided tables is still too high. Tables 1 and 4 could be collapsed with the corresponding tables 2/3 and 5/6. Data such as country, model type, time horizon and funding source should be provided in the same table as type of economic evaluation, perspective, and other model characteristics. Data such as impact of varicella vaccination on HZ incidence and herd protection should be included in the same table as vaccine characteristics. Some data are presented twice in different tables. For example, age at varicella vaccination is provided in Tables 2 and 7. Further, age at vaccination, dose schedule, and comparator are included in the table on economic results. But these are characteristics of the underlying models. Therefore, I would suggest including it in tables on general study characteristics or model characteristics.

2: The cost-effectiveness results have been inflated to 2010 values, which is still outdated. Those values should be updated.

Discretionary revisions:
1: Critical appraisal is mentioned and a few sentences on the critical appraisal have been added in the text. I would still recommend to include a summary figure about the critical appraisal.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I published a systematic review on the cost-effectiveness of herpes zoster vaccination.